response to your question:
One would think so but hope not. I would think your observation is correct and the company practically would buy Medify but as Medify is the incumbent Pink sheet listed entity, then the legal process is the other way around with the new company emerging.
Now maybe you’re onto something here. If the company is buying Medify through a reverse merger and the surviving entity becomes the new Pink Sheet listed company, then maybe this will allow Medify the time to breathe whilst it pushes to revenue. Also, the surviving and now new lead entity has a free run on it’s listing. It’s revenue and PR will lead the news stories and with revenue being published, as everyone has said, will drive the pps up. So in real terms, the investors would in this scenario, keep hold of Medify for long term investment, whilst now owning stock in a company that has revenue and history. Now that would be sweet and I would be interested in any thoughts.
To be honest that makes perfect sense. Medify is kept going whilst it develops in-line with the NHS, and the parent company now has a new operational subsidiary which, and thus the share holders now gain shares in a profitable company. Maybe Ian has come up with a perfect scenario that we can all benefit from, address the past, gives the company the immediate chance of success and I don’t; think anyone would complain if Medify progressed to revenue without burdening the parent company (pinks listed entity) and they have shares that have a real chance of climbing?
AI
